Drug Type Prophylactic vaccine, mRNA vaccine |
Synonyms BNT 162B1 |
Target |
Mechanism SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2/3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | US | 29 Apr 2020 | |
COVID-19 | Phase 3 | AR | 29 Apr 2020 | |
COVID-19 | Phase 3 | BR | 29 Apr 2020 | |
COVID-19 | Phase 3 | DE | 29 Apr 2020 | |
COVID-19 | Phase 3 | ZA | 29 Apr 2020 | |
COVID-19 | Phase 3 | TR | 29 Apr 2020 |
Phase 1 | 144 | Placebo (Placebo, 18-55 Years of Age) | lrulqwfktr(ofojaujwgw) = rtouxiwbqr wsnloitytz (nqmijtqyux, nbgbnpkasm - sfpgwvhwfw) View more | - | 18 Sep 2023 | ||
Placebo (Placebo, 65-85 Years of Age) | lrulqwfktr(ofojaujwgw) = mynylalxfj wsnloitytz (nqmijtqyux, vxyqddsgih - pouyuvrkfy) View more | ||||||
Phase 1 | 144 | whgheienjm(tmtpvyguzq) = Fever kuwvqylkeg (jfbrinixiv ) | Positive | 01 Jun 2021 | |||
Placebo | |||||||
NCT04368728 (Pubmed) Manual | Phase 1 | 195 | qtysuzvwqy(dhtmfudxsz) = BNT162b2 was associated with a lower incidence and severity of systemic reactions than BNT162b1 vqhnbmfvap (hkgzbozbxf ) View more | Positive | 17 Dec 2020 | ||
Placebo |